Department of Anesthesiology and Critical Care, Beaujon Hospital, DMU Parabol, AP-HP Nord, Paris.
Department of Anesthesiology and Critical Care, APH-HP, Bicêtre Hôpitaux Universitaires Paris-Saclay, Université Paris Saclay, Le Kremlin Bicêtre.
Eur J Emerg Med. 2024 Aug 1;31(4):287-293. doi: 10.1097/MEJ.0000000000001138. Epub 2024 Apr 30.
Occurrence of mydriasis during the prehospital management of traumatic brain injury (TBI) may suggest severe intracranial hypertension (ICH) subsequent to brain herniation. The initiation of hyperosmolar therapy to reduce ICH and brain herniation is recommended. Whether mannitol or hypertonic saline solution (HSS) should be preferred is unknown.
The objective of this study is to assess whether HSS, compared with mannitol, is associated with improved survival in adult trauma patients with TBI and mydriasis.
DESIGN/SETTING AND PARTICIPANTS: A retrospective observational cohort study using the French Traumabase national registry to compare the ICU mortality of patients receiving either HSS or mannitol. Patients aged 16 years or older with moderate to severe TBI who presented with mydriasis during prehospital management were included.
We performed propensity score matching on a priori selected variables [i.e. age, sex and initial Coma Glasgow Scale (GCS)] with a ratio of 1 : 3 to ensure comparability between the two groups. The primary outcome was ICU mortality. The secondary outcomes were regression of pupillary abnormality during prehospital management, pulsatility index and diastolic velocity on transcranial Doppler within 24 h after TBI, early ICU mortality (within 48 h), ICU and hospital length of stay.
Of 31 579 patients recorded in the registry between 2011 and 2021, 1417 presented with prehospital mydriasis and were included: 1172 (82.7%) received mannitol and 245 (17.3%) received HSS. After propensity score matching, 720 in the mannitol group matched 240 patients in the HSS group. Median age was 41 years [interquartile ranges (IQR) 26-60], 1058 were men (73%) and median GCS was 4 (IQR 3-6). No significant difference was observed in terms of characteristics and prehospital management between the two groups. ICU mortality was lower in the HSS group (45%) than in the mannitol group (54%) after matching [odds ratio (OR) 0.68 (0.5-0.9), P = 0.014]. No differences were identified between the groups in terms of secondary outcomes.
In this propensity-matched observational study, the prehospital osmotherapy with HSS in TBI patients with prehospital mydriasis was associated with a lower ICU mortality compared to osmotherapy with mannitol.
创伤性脑损伤(TBI)患者在院前管理期间出现瞳孔散大可能提示脑疝后继发性颅内高压(ICH)。建议开始使用高渗疗法以降低 ICH 和脑疝。但尚不清楚甘露醇和高渗盐水(HSS)哪种更有效。
本研究旨在评估与甘露醇相比,HSS 是否可改善创伤性 TBI 伴瞳孔散大的成年患者的生存率。
设计/地点和参与者:本研究是一项使用法国 Traumabase 国家登记处的回顾性观察性队列研究,旨在比较 HSS 与甘露醇治疗 ICU 死亡率。纳入年龄在 16 岁及以上、在院前管理期间出现瞳孔散大且有中度至重度 TBI 的患者。
使用倾向评分匹配预先选择的变量(即年龄、性别和初始昏迷格拉斯哥评分(GCS)),匹配比例为 1:3,以确保两组之间的可比性。主要结局是 ICU 死亡率。次要结局是院前管理期间瞳孔异常的消退情况、TBI 后 24 小时内经颅多普勒的搏动指数和舒张速度、伤后 48 小时内早期 ICU 死亡率、ICU 和住院时间。
在 2011 年至 2021 年期间登记的 31579 例患者中,有 1417 例出现院前瞳孔散大,其中 1172 例(82.7%)接受甘露醇治疗,245 例(17.3%)接受 HSS 治疗。经过倾向评分匹配后,甘露醇组 720 例与 HSS 组 240 例匹配。中位年龄为 41 岁[四分位间距(IQR)26-60],1058 例为男性(73%),中位 GCS 为 4(IQR 3-6)。两组之间的特征和院前管理无显著差异。匹配后 HSS 组 ICU 死亡率(45%)低于甘露醇组(54%)[比值比(OR)0.68(0.5-0.9),P =0.014]。两组间次要结局无差异。
在这项倾向评分匹配的观察性研究中,与甘露醇相比,TBI 患者院前 HSS 治疗伴院前瞳孔散大患者的 ICU 死亡率较低。